Table 4.

Relationship between plasma levels of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 and risk of colon cancer among 137 cases and 262 controls nested in the Nurses' Health Study, 1989-2000

Quartile
Ptrend
1234
IGF-I
    Median (ng/mL)95133170230
        Cases/Controls26/6931/6236/6644/65
        RR* (95% CI)1.001.14 (0.59-2.20)1.38 (0.71-2.71)1.95 (0.97-3.91)0.09
        RR (95% CI)1.001.19 (0.60-2.37)1.46 (0.07-3.08)2.17 (0.96-4.88)0.03
IGFBP-3
    Median2,9203,8234,6025,443
        Cases/Controls30/6436/7137/6234/65
        RR* (95% CI)1.001.08 (0.56-2.12)1.36 (0.71-2.61)1.20 (0.62-2.30)0.62
        RR (95% CI)1.000.85 (0.41-1.78)1.04 (0.51-2.16)0.81 (0.38-1.75)0.12
IGF-I/IGFBP-3
    Median0.090.120.140.18
        Cases/Controls24/6731/6734/6248/66
        RR (95% CI)1.001.88 (0.90-3.94)2.33 (1.11-4.87)2.82 (1.35-5.88)0.01
  • * Adjusted for BMI, physical activity, pack-years smoked, and alcohol intake as continuous variables, family history of colorectal cancer, aspirin use, history of screening, menopausal status, and use of hormone replacement therapy.

  • Adjusted for BMI, physical activity, pack-years smoked, and alcohol intake as continuous variables, family history of colorectal cancer, aspirin use, history of screening, menopausal status, and use of hormone replacement therapy and IGF-I or IGFBP-3.